Background: Chronic inflammation is increasingly recognized as a crucial contributor to sarcopenia pathogenesis, but accurate diagnosis remains a challenge.
Aim: Our study aims to investigate the relationship between sarcopenia and the Systemic Immune-Inflammation Index (SII), a comprehensive indicator of inflammation.
Methods: This cross-sectional study enrolled 632 patients. All participants underwent a comprehensive geriatric assessment. Sarcopenia was assessed through the evaluation of handgrip strength and calf circumference. To determine the SII, we used the formula: Platelet count (10/mm)×Neutrophil count (10/mm) / Lymphocyte count (10/mm).
Results: The average age of the participants was 74.8 ± 6.4, and 62.3% (n = 394) were female. Patients were grouped as non-sarcopenic and sarcopenic. The non-sarcopenic group had 536 patients (84.8%), while the sarcopenic group comprised 96 patients (15.2%). Sarcopenic patients showed a higher median SII score than the non-sarcopenic group (p < 0.001). Multivariate logistic regression analysis revealed that the SII score was significantly and independently associated with sarcopenia even after adjusting for potential confounding factors (β = 1.002, 95% CI = 1.001-1.003, p < 0.001). The ROC analysis identified the optimal cut-off for SII in predicting sarcopenia as > 765. At this threshold, the negative predictive values were determined to be 88.1%, with a specificity of 88%.
Conclusion: SII is significantly associated with sarcopenia in a geriatric outpatient population, and a population-specific SII cut-off may serve as a novel, simple, and practical biomarker for diagnosing sarcopenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1186/s12877-025-05686-2 | DOI Listing |
Biomark Res
January 2025
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University180 Fenglin Road, Shanghai, 200032, China.
Background: Predicting the efficacy of immune-based therapy in patients with unresectable hepatocellular carcinoma (HCC) remains a clinical challenge. This study aims to evaluate the prognostic value of the systemic immune-inflammation index (SII) in forecasting treatment response and survival outcomes for HCC patients undergoing immune-based therapy.
Methods: We analyzed a cohort of 268 HCC patients treated with immune-based therapy from January 2019 to March 2023.
World J Surg Oncol
January 2025
Hunan University of Traditional Chinese Medicine, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, No. 233, Cai'e North Road, Kaifu District, Changsha, Hunan, 410005, China.
Background: In recent years, the association between systemic immune-inflammation index (SII) and the prognosis of patients with colorectal cancer (CRC) has remained a topic of considerable debate. To address this, the present study was carried out to investigate the prognostic significance of SII in CRC.
Methods: Databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science were scrutinized up to March 27, 2024.
BMC Geriatr
January 2025
Faculty of Medicine, Department of Geriatric Medicine, Gazi University, Ankara, 06560, Turkey.
Background: Chronic inflammation is increasingly recognized as a crucial contributor to sarcopenia pathogenesis, but accurate diagnosis remains a challenge.
Aim: Our study aims to investigate the relationship between sarcopenia and the Systemic Immune-Inflammation Index (SII), a comprehensive indicator of inflammation.
Methods: This cross-sectional study enrolled 632 patients.
IL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.
View Article and Find Full Text PDFJ Inflamm Res
January 2025
Department of Thoracic Surgery, The First People's Hospital of Shuangliu District (West China Airport Hospital of Sichuan University), Chendu, Sichuan Province, 610200, People's Republic of China.
Background: Systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers based on neutrophil, platelet and lymphocyte counts. Atherosclerosis is a chronic inflammatory vascular disease. This study aimed to verify the predictive value of the clinical parameters such as systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) for the severity in Large Artery Atherosclerosis (LAA) stroke patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!